314 related articles for article (PubMed ID: 30830867)
1. Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells.
Shimizu H; Takeishi S; Nakatsumi H; Nakayama KI
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830867
[TBL] [Abstract][Full Text] [Related]
2. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
3. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
[TBL] [Abstract][Full Text] [Related]
4. The FBXW7 tumor suppressor inhibits breast cancer proliferation and promotes apoptosis by targeting MTDH for degradation.
Chen X; Li XY; Long M; Wang X; Gao ZW; Cui Y; Ren J; Zhang Z; Liu C; Dong K; Zhang H
Neoplasma; 2018; 65(2):201-209. PubMed ID: 29534580
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
[TBL] [Abstract][Full Text] [Related]
6. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
Hidayat M; Mitsuishi Y; Takahashi F; Tajima K; Yae T; Miyahara K; Hayakawa D; Winardi W; Ihara H; Koinuma Y; Wirawan A; Nurwidya F; Kato M; Kobayashi I; Sasaki S; Takamochi K; Hayashi T; Suehara Y; Moriyama M; Moriyama H; Habu S; Takahashi K
Bosn J Basic Med Sci; 2019 Nov; 19(4):355-367. PubMed ID: 31202256
[TBL] [Abstract][Full Text] [Related]
7. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
Pillai SG; Li S; Siddappa CM; Ellis MJ; Watson MA; Aft R
Breast Cancer Res; 2018 Jan; 20(1):2. PubMed ID: 29291741
[TBL] [Abstract][Full Text] [Related]
8. Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow.
Buschhaus JM; Humphries BA; Eckley SS; Robison TH; Cutter AC; Rajendran S; Haley HR; Bevoor AS; Luker KE; Luker GD
Oncogene; 2020 Aug; 39(34):5649-5662. PubMed ID: 32678295
[TBL] [Abstract][Full Text] [Related]
9. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.
Borgen E; Rypdal MC; Sosa MS; Renolen A; Schlichting E; Lønning PE; Synnestvedt M; Aguirre-Ghiso JA; Naume B
Breast Cancer Res; 2018 Oct; 20(1):120. PubMed ID: 30322396
[TBL] [Abstract][Full Text] [Related]
10. The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.
Jiang X; Wang Y; Guo L; Wang Y; Miao T; Ma L; Wei Q; Lin X; Mao JH; Zhang P
Breast Cancer Res; 2024 Mar; 26(1):37. PubMed ID: 38454442
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.
Hoffmann O; Schroer-Zuendorf IA; Kasimir-Bauer S; Oberhoff C; Kimmig R; Heubner M
Arch Gynecol Obstet; 2015 Nov; 292(5):1117-25. PubMed ID: 25986892
[TBL] [Abstract][Full Text] [Related]
12. Ca
Ohya S; Kajikuri J; Endo K; Kito H; Elboray EE; Suzuki T
Cancer Sci; 2021 Sep; 112(9):3769-3783. PubMed ID: 34181803
[TBL] [Abstract][Full Text] [Related]
13. FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
Saffie R; Zhou N; Rolland D; Önder Ö; Basrur V; Campbell S; Wellen KE; Elenitoba-Johnson KSJ; Capell BC; Busino L
Cancer Res; 2020 Jun; 80(12):2498-2511. PubMed ID: 32350066
[TBL] [Abstract][Full Text] [Related]
14. The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors.
Koga Y; Iwatsuki M; Yamashita K; Kiyozumi Y; Kurashige J; Masuda T; Eto K; Iwagami S; Harada K; Ishimoto T; Baba Y; Yoshida N; Miyanari N; Takamori H; Ajani JA; Baba H
Gastric Cancer; 2019 Nov; 22(6):1100-1108. PubMed ID: 30854619
[TBL] [Abstract][Full Text] [Related]
15. MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7.
Ding J; Zhao Z; Song J; Luo B; Huang L
Acta Biochim Biophys Sin (Shanghai); 2018 Jun; 50(6):597-604. PubMed ID: 29701752
[TBL] [Abstract][Full Text] [Related]
16. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
Xiao Y; Yin C; Wang Y; Lv H; Wang W; Huang Y; Perez-Losada J; Snijders AM; Mao JH; Zhang P
Mol Oncol; 2018 Jun; 12(6):883-895. PubMed ID: 29633504
[TBL] [Abstract][Full Text] [Related]
17. miR-367 promotes tumor growth by inhibiting FBXW7 in NSCLC.
Xiao G; Gao X; Sun X; Yang C; Zhang B; Sun R; Huang G; Li X; Liu J; Du N; Liu D; Liang R; Ren H; Qin S
Oncol Rep; 2017 Aug; 38(2):1190-1198. PubMed ID: 28656290
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of
Gstalder C; Liu D; Miao D; Lutterbach B; DeVine AL; Lin C; Shettigar M; Pancholi P; Buchbinder EI; Carter SL; Manos MP; Rojas-Rudilla V; Brennick R; Gjini E; Chen PH; Lako A; Rodig S; Yoon CH; Freeman GJ; Barbie DA; Hodi FS; Miles W; Van Allen EM; Haq R
Cancer Discov; 2020 Sep; 10(9):1296-1311. PubMed ID: 32371478
[TBL] [Abstract][Full Text] [Related]
19. Loss of Fbxw7 expression is a predictor of recurrence in colorectal liver metastasis.
Kawashita Y; Morine Y; Ikemoto T; Saito Y; Iwahashi S; Yamada S; Higashijima J; Imura S; Ogawa H; Yagi T; Shimada M
J Hepatobiliary Pancreat Sci; 2017 Oct; 24(10):576-583. PubMed ID: 28846828
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients.
Ibusuki M; Yamamoto Y; Shinriki S; Ando Y; Iwase H
Cancer Sci; 2011 Feb; 102(2):439-45. PubMed ID: 21134077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
